Ivermectin for onchocercal eye disease (river blindness) (Review)

In Abiose 1993 communities endemic for onchocerciasis were
treated, that is everyone aged five years and above received ivermectin
or placebo, however, children under the age of 15 years
were not examined at follow-up. Although this means that not everyone
treated was examined, it is hard to envisage that this would
bias the resulting effect estimates as very few events would be expected
in people aged five to 15 and there is no reason to suppose
that the effect of ivermectin will be different in this age group.
Selective reporting
Data were reported rather sparsely for most outcomes. Table 3
shows the outcome reporting grid. There is considerable potential
for selective outcome reporting.
Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14